Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)

Arthritis Research and Therapy

Volumn 12, Issue 2, 2010, Pages

  Stohl, William ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; BELIMUMAB; HYBRID PROTEIN; MONOCLONAL ANTIBODY; TACI RECEPTOR IGG FC FRAGMENT FUSION PROTEIN; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN; TNFSF13B PROTEIN, HUMAN;

COMPLEX FORMATION; EDITORIAL; HUMAN; IN VITRO STUDY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FAMILY; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; B LYMPHOCYTE; BLOOD; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; NOTE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN MULTIMERIZATION;

ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEIN MULTIMERIZATION; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 77951056252     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2976     Document Type: Editorial

References (12)

1. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'era M, Gross JA. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010, 12:R48. 10.1186/ar2959, 20302641.
2. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone T-S. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002, 169:4314-4321.
3. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710. 2195729, 10587360, 10.1084/jem.190.11.1697.
4. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999. 10.1038/35010115, 10801128.
5. Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, Frank D, Rice J, Diamond B, Yu KOA, Porcelli S, Davidson A. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006, 116:724-734. 1366500, 16485042, 10.1172/JCI26385.
6. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, Bixler SA, Ambrose CM, Scott ML, Stohl W. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand Mixed 2328 mice deficient in BAFF. J Immunol 2006, 177:2671-2680.
7. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44:1313-1319. 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S, 11407690.
8. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459. 10.1002/art.23678, 18668552.
9. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168-1178. 10.1002/art.24699, 19714604.
10. Navarra S, Guzman R, Gallacher A, Levy RA, Li EK, Thomas M, Jimenez R, Leon M, Hall S, Lan JL, Nasonov E, Tanasescu C, Kim HY, Pineda L, Zhong ZJ, Freimuth W, Petri MA, . BLISS-52 Study Group Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study [Abstract]. Arthritis Rheum 2009, 60:3859. BLISS-52 Study Group.
11. Stein JV, López-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodríguez D, Gómez-Caro R, de Jong J, Martínez-A C, Medema JP, Hahne M. APRIL modulates B and T cell immunity. J Clin Invest 2002, 109:1587-1598. 151011, 12070306.
12. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat A-F, Bossen C, Schneider P, Huard B, Lambert P-H, Siegrist C-A. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008, 111:2755-2764. 10.1182/blood-2007-09-110858, 18180376.